APA (7th ed.) Citation

AI, G., NF, I., N, A., R, M., HA, N., DS, E., . . . AMEM, S. (2024). Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial. Diseases (Basel, Switzerland), 12(8), . https://doi.org/10.3390/diseases12080186

Chicago Style (17th ed.) Citation

AI, Gad, Ibrahim NF, Almadani N, Mahfouz R, Nofal HA, El-Rafey DS, Ali HT, El-Hawary AT, and Sadek AMEM. "Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial." Diseases (Basel, Switzerland) 12, no. 8 (2024). https://doi.org/10.3390/diseases12080186.

MLA (9th ed.) Citation

AI, Gad, et al. "Therapeutic Effects of Semaglutide on Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus and Obesity: An Open-Label Controlled Trial." Diseases (Basel, Switzerland), vol. 12, no. 8, 2024, https://doi.org/10.3390/diseases12080186.